Related Experiment Video
Updated: May 3, 2026
07:43
Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
Published on: January 17, 2018
18.5K
Cabergoline treatment in acromegaly: pros
Mónica Marazuela1, Ana Ramos-Leví, Miguel Sampedro-Núñez
1Department of Endocrinology and Nutrition, Hospital Universitario de la Princesa, Instituto de Investigación Princesa, Universidad Autónoma de Madrid, C/Diego de León 62, 28006, Madrid, Spain, monica.marazuela@salud.madrid.org.
Endocrine
|February 18, 2014
Summary
Cabergoline, a dopamine agonist, effectively manages acromegaly by lowering growth hormone and IGF-I. Its oral convenience and lower cost make it an attractive treatment option for long-term disease control.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Acromegaly is a chronic endocrine disorder characterized by excessive growth hormone production.
- Medical management of acromegaly often requires long-term treatment to control hormone levels and tumor growth.
Purpose of the Study:
- To evaluate the efficacy and suitability of cabergoline for acromegaly management.
- To assess cabergoline's role as a primary or add-on therapy in acromegaly.
Main Methods:
- Review of studies investigating cabergoline's effects on growth hormone (GH) and insulin-like growth factor-I (IGF-I) levels.
- Analysis of cabergoline's impact on pituitary tumor cell proliferation and apoptosis.
- Comparison of cabergoline with somatostatin analogs (SSA) and pegvisomant (PEG) in terms of efficacy, administration, and cost.
Main Results:
- Cabergoline demonstrates efficacy in reducing GH and IGF-I levels.
- Observed antiproliferative and pro-apoptotic effects on pituitary tumor cells.
- Effective as monotherapy or add-on treatment for patients resistant to or not fully controlled by SSA or PEG.
Conclusions:
- Cabergoline is an effective and well-tolerated option for acromegaly treatment.
- Oral administration, favorable cost, and manageable side effect profile support its use in long-term acromegaly management.
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
1.9K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.9K
00:59Direct-Acting Cholinergic Agonists: Pharmacological Actions
2.3K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
2.3K
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
1.8K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.8K
01:31Direct-Acting Cholinergic Agonists: Pharmacokinetics
2.0K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
2.0K
01:20Myasthenia Gravis: Overview and Treatment
3.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.7K